Outcome of AIDS-associated cryptococcal meningitis initially treated with 200 mg/day or 400 mg/day of fluconazole |
| |
Authors: | CF Schaars GA Meintjes C Morroni FA Post G Maartens |
| |
Affiliation: | (1) Division of Infectious Diseases, University of Cape Town, Cape Town, South Africa;(2) Division of Clinical Pharmacology, University of Cape Town, Cape Town, South Africa;(3) School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa;(4) Canisius Wilhelmina Hospital, Nijmegen, The Netherlands;(5) King's College London School of Medicine, London, UK |
| |
Abstract: | Background AIDS-associated cryptococcal meningitis has a high mortality. Fluconazole was the only systemic antifungal therapy available in our centre. From 1999–2001 we used low-dose fluconazole (200 mg daily initially), and did not offer therapy to patients perceived to have poor prognoses. In 2001 donated fluconazole became available, allowing us to use standard doses (400 mg daily initially). Antiretroviral therapy was not available during the study period. |
| |
Keywords: | |
本文献已被 SpringerLink 等数据库收录! |
|